Verheijen, Remy B.
van der Biessen, Diane A. J.
Hotte, Sebastien J.
Siu, Lillian L.
Spreafico, Anna
de Jonge, Maja J. A.
Pronk, Linda C.
De Vos, Filip Y. F. L.
Schnell, David
Hirte, Hal W.
Steeghs, Neeltje
Lolkema, Martijn P.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
https://doi.org/10.1007/s11523-018-00618-0
Funding for this research was provided by:
Boehringer Ingelheim
Article History
First Online: 11 February 2019
Compliance with Ethical Standards
:
: This work was supported by Boehringer Ingelheim, Ingelheim am Rhein, Germany. BI 853520 is an asset of Boehringer Ingelheim. This article was published open access under a Springer Compact agreement with Dutch universities and Academy institutes.
: Remy B. Verheijen is an employee of AstraZeneca. Lillian L. Siu reports clinical trial funding (for her institution) for this study provided by from Boehringer Ingelheim. Linda C. Pronk and David Schnell are employees of Boehringer Ingelheim. Filip Y. F. L. De Vos has been paid for expert testimonial by Bristol-Myers Squibb, and received grants from Novartis. Hal W. Hirte has received honoraria from AstraZeneca, Roche, and Merck. Diane A. J. van der Biessen, Sebastien J. Hotte, Anna Spreafico, Maja J. A. de Jonge, Neeltje Steeghs, and Martijn P. Lolkema declare no conflicts of interest.